CCL15抗体 新品

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human breast cancer tissue using P03801(CCL15 Antibody) at dilution 1/25. (Original magnification: ×200)    

  
  

CCL15 (C-C motif chemokine ligand 15), also known as leukotactin-1 or HCC-2. is a member of the CC chemokine family involved in immune cell recruitment and inflammatory responses. It binds to receptors CCR1. CCR3. and CCR5. mediating chemotaxis of monocytes, T cells, eosinophils, and dendritic cells. CCL15 is constitutively expressed in tissues such as the liver, intestines, and placenta, and its production is upregulated during inflammation, infection, or tissue injury. Dysregulated CCL15 signaling has been implicated in pathologies like inflammatory bowel disease, rheumatoid arthritis, and cancers (e.g., hepatocellular carcinoma, colorectal cancer), where it may promote tumor growth, angiogenesis, and metastasis by modulating the tumor microenvironment.

CCL15 antibodies are essential tools for studying its biological roles and therapeutic potential. Polyclonal or monoclonal antibodies targeting CCL15 enable the detection of its expression patterns in tissues or biofluids, serving as biomarkers for disease progression. Neutralizing antibodies that block CCL15-receptor interactions are under investigation for their ability to suppress inflammation or tumorigenesis in preclinical models. Challenges include optimizing antibody specificity due to structural similarities among CC chemokines and addressing potential off-target effects. Recent studies highlight CCL15's dual role in immune regulation and cancer, driving interest in antibody-based therapies to modulate its activity in precision medicine approaches.